CoChat

Arsenic Induces Functional Re-Expression of Estrogen Receptor α by Demethylation of DNA in Estrogen Receptor-Negative Human Breast Cancer

Open access

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Estrogen receptor α (ERα) is a marker predictive for response of breast cancers to endocrine therapy. About 30% of breast cancers, however, are hormone- independent because of lack of ERα expression. New strategies are needed for re-expression of ERα and sensitization of ER-negative breast cancer cells to selective ER modulators. The present report shows that arsenic trioxide induces reactivated ERα, providing a target for therapy with ER antagonists. Exposure of ER-negative breast cancer cells to arsenic trioxide leads to re-expression of ERα mRNA and functional ERα protein in in vitro and in vivo. Luciferase reporter gene assays and 3-(4,5-dimethylthiazol-2-yl)- 5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assays show that, upon exposure to arsenic trioxide, formerly unresponsive, ER-negative MDA-MB-231 breast cancer cells become responsive to ER antagonists, 4-hydroxytamoxifen and ICI 182,780. Furthermore, methylation- specific PCR and bisulfite-sequencing PCR assays show that arsenic trioxide induces partial demethylation of the ERα promoter. A methyl donor, S-adenosylmethionine (SAM), reduces the degree of arsenic trioxide-induced re-expression of ERα and demethylation. Moreover, Western blot and ChIP assays show that arsenic trioxide represses expression of DNMT1 and DNMT3a along with partial dissociation of DNMT1 from the ERα promoter. Thus, arsenic trioxide exhibits a previously undefined function which induces re-expression ERα in ER-negative breast cancer cells through demethylation of the ERα promoter. These findings could provide important information regarding the application of therapeutic agents targeting epigenetic changes in breast cancers and potential implication of arsenic trioxide as a new drug for the treatment of ER-negative human breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0035957

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 ERα mRNA and protein re-expression induced by arsenic trioxide in MDA-MB-231 cells (A) and Hs578T cells (B). ERα protein re-expression induced by AZA (2.5 μmol/L for 4 days) in MDA-MB-231 cells (C). RT-PCR and Western blotting analysis showed the re-expression of ER mRNA and protein after exposure of cells to arsenic trioxide (1, 2, 4 μmol/L for 6 days), whereas SAM (200 μmol/L for 6 days) reduced the degree of re-expression. The ER-positive prototype, MCF-7, was used as a positive control; untreated ER-negative MDA-MB-231 cells were used as a negative control. GAPDH and β-Actin provided a control for the amount of intact RNA and protein used in the reactions. ## P<0.01 compared with control cells. # P<0.05 compared with control cells. *P<0.05 compared with cells exposed to 1 μM arsenic trioxide.
Figure 1 ERα mRNA and protein re-expression induced by arsenic trioxide in MDA-MB-231 cells (A) and Hs578T cells (B). ERα protein re-expression induced by AZA (2.5 μmol/L for 4 days) in MDA-MB-231 cells (C). RT-PCR and Western blotting analysis showed the re-expression of ER mRNA and protein after exposure of cells to arsenic trioxide (1, 2, 4 μmol/L for 6 days), whereas SAM (200 μmol/L for 6 days) reduced the degree of re-expression. The ER-positive prototype, MCF-7, was used as a positive control; untreated ER-negative MDA-MB-231 cells were used as a negative control. GAPDH and β-Actin provided a control for the amount of intact RNA and protein used in the reactions. ## P<0.01 compared with control cells. # P<0.05 compared with control cells. *P<0.05 compared with cells exposed to 1 μM arsenic trioxide.CC BY · PubMed Central
Figure 2 Re-expression of functional ERα in ER-negative MDA-MB-231 and Hs578T cells by arsenic trioxide. (A) Effect of arsenic trioxide (2 μmol/L for 6 days), E2 (10 nmol/L for 24 hr), OHT (10 μmol/L for 24 hr), and ICI (2 μmol/L for 24 hr) on cell growth was determined by MTS. MCF-7 and MDA-MB-231 cells were exposed to E2, OHT or ICI for 24 hr before assay. In addition, MDA-MB-231 cells were exposed to arsenic trioxide (2 μmol/L for 6 days), as described, along with E2, OHT or ICI for 24 hr before MTS assay. This experiment was repeated twice with similar results. (B) The transcriptional activities of re-expressed ERα was examined in MDA-MB-231 cells by luciferase reporter gene assay. Cells were transiently co-transfected with 0.5 μg of pERE-TATALuc+, 0.2 μg of rERa/pCI, and 0.1 μg of phRL-tk as an positive control; untreated MDA-MB-231 cells were transiently co-transfected with 0.5 μg of pERE-TATALuc+ and 0.1 μg of phRL-tk as a negative control. MDA-MB-231 cells were exposed to arsenic trioxide alone (2 μmol/L for 6 days), or in combination with E2 (10 nmol/L) or ICI (2 μmol/L) for 24 hr. The cell lysates were analyzed by use of the Dual-Luciferase Reporter Assay System kit. Ethanol solvent was used as control, and transcriptional activity was presented as fold of control. Values are presented as the means ± SD of three independent experiments. (C) Expression of ERα and its target genes (pS2 and GREB1) in MDA-MB-231 cells. Before RT-PCR was performed, cells untreated or pretreated with arsenic trioxide were exposed to SAM (200 μmol/L for 6 days), OHT (10 μmol/L for 24 hr), ICI (2 μmol/L for 24 hr), or vehicle in fresh estrogen-free medium. This experiment was repeated twice with similar results. (D) Expression of ERα target genes pS2 and GREB1) in Hs578T cells. Before RT-PCR was performed, cells untreated or pretreated with arsenic trioxide were exposed to SAM (200 μmol/L for 6 days), AZA (2.5 μmol/L for 4 days), or vehicle in fresh estrogen-free medium. This experiment was repeated twice with similar results.
Figure 2 Re-expression of functional ERα in ER-negative MDA-MB-231 and Hs578T cells by arsenic trioxide. (A) Effect of arsenic trioxide (2 μmol/L for 6 days), E2 (10 nmol/L for 24 hr), OHT (10 μmol/L for 24 hr), and ICI (2 μmol/L for 24 hr) on cell growth was determined by MTS. MCF-7 and MDA-MB-231 cells were exposed to E2, OHT or ICI for 24 hr before assay. In addition, MDA-MB-231 cells were exposed to arsenic trioxide (2 μmol/L for 6 days), as described, along with E2, OHT or ICI for 24 hr before MTS assay. This experiment was repeated twice with similar results. (B) The transcriptional activities of re-expressed ERα was examined in MDA-MB-231 cells by luciferase reporter gene assay. Cells were transiently co-transfected with 0.5 μg of pERE-TATALuc+, 0.2 μg of rERa/pCI, and 0.1 μg of phRL-tk as an positive control; untreated MDA-MB-231 cells were transiently co-transfected with 0.5 μg of pERE-TATALuc+ and 0.1 μg of phRL-tk as a negative control. MDA-MB-231 cells were exposed to arsenic trioxide alone (2 μmol/L for 6 days), or in combination with E2 (10 nmol/L) or ICI (2 μmol/L) for 24 hr. The cell lysates were analyzed by use of the Dual-Luciferase Reporter Assay System kit. Ethanol solvent was used as control, and transcriptional activity was presented as fold of control. Values are presented as the means ± SD of three independent experiments. (C) Expression of ERα and its target genes (pS2 and GREB1) in MDA-MB-231 cells. Before RT-PCR was performed, cells untreated or pretreated with arsenic trioxide were exposed to SAM (200 μmol/L for 6 days), OHT (10 μmol/L for 24 hr), ICI (2 μmol/L for 24 hr), or vehicle in fresh estrogen-free medium. This experiment was repeated twice with similar results. (D) Expression of ERα target genes pS2 and GREB1) in Hs578T cells. Before RT-PCR was performed, cells untreated or pretreated with arsenic trioxide were exposed to SAM (200 μmol/L for 6 days), AZA (2.5 μmol/L for 4 days), or vehicle in fresh estrogen-free medium. This experiment was repeated twice with similar results.CC BY · PubMed Central
Figure 3 Arsenic trioxide induces functional re-expression of ERα in vivo. (A) Expression of ERα mRNA and its target genes (pS2 and GREB1) in MDA-MB-231 tumors. Arsenic trioxide (2 mg/kg BW) was administered i.p. in 100 μl of sterile saline for 4 weeks. The ER-positive prototype, MCF-7, was used as a positive control. C1–C5: control group, A1–A5: arsenic trioxide-treated group. (B) Expression of ERα protein in MDA-MB-231 tumors. The relative expression level of ERα protein is represented in a scatter plot. (C) Representative immunohistochemistry for ERα in MDA-MB-231 tumors using an anti- ERα polyclonal antibody.
Figure 3 Arsenic trioxide induces functional re-expression of ERα in vivo. (A) Expression of ERα mRNA and its target genes (pS2 and GREB1) in MDA-MB-231 tumors. Arsenic trioxide (2 mg/kg BW) was administered i.p. in 100 μl of sterile saline for 4 weeks. The ER-positive prototype, MCF-7, was used as a positive control. C1–C5: control group, A1–A5: arsenic trioxide-treated group. (B) Expression of ERα protein in MDA-MB-231 tumors. The relative expression level of ERα protein is represented in a scatter plot. (C) Representative immunohistochemistry for ERα in MDA-MB-231 tumors using an anti- ERα polyclonal antibody.CC BY · PubMed Central
Figure 4 Methylation analysis of the ERα promoter by MSP in MDA-MB-231 cells. (A) A 2.5 kb genomic sequence of the ERα promoter, analyzed by the online program, www.urogene.org/methprimer, revealed the presence of a high GC percentage CpG islands (blue) between relative positions 2000 and 2500. Position 2000 indicates the transcription start site (TSS, arrow). A region of high CpG (red vertical bars) density was chosen for MSP analysis. This region includes 28 CpG dinucleotides. (B), Methylation analysis of the ERα promoter by MSP in breast cancer cell lines. Sensitivity of the utilized MSP primers was determined by a dilution series of methylated DNA with unmethylated DNA. At least 1% of methylated DNA (∼0.1 ng) can be detected with the ER MSP primers. In each set, M primer pairs anneal only to sequences that are methylated before bisulfite treatment, whereas the U primer pairs anneal only to sequences that are unmethylated.
Figure 4 Methylation analysis of the ERα promoter by MSP in MDA-MB-231 cells. (A) A 2.5 kb genomic sequence of the ERα promoter, analyzed by the online program, www.urogene.org/methprimer, revealed the presence of a high GC percentage CpG islands (blue) between relative positions 2000 and 2500. Position 2000 indicates the transcription start site (TSS, arrow). A region of high CpG (red vertical bars) density was chosen for MSP analysis. This region includes 28 CpG dinucleotides. (B), Methylation analysis of the ERα promoter by MSP in breast cancer cell lines. Sensitivity of the utilized MSP primers was determined by a dilution series of methylated DNA with unmethylated DNA. At least 1% of methylated DNA (∼0.1 ng) can be detected with the ER MSP primers. In each set, M primer pairs anneal only to sequences that are methylated before bisulfite treatment, whereas the U primer pairs anneal only to sequences that are unmethylated.CC BY · PubMed Central
Figure 5 Methylation analysis of the ERα promoter by BSP in breast cancer cells. (A)Shown is a representative bisulfite sequence analysis for the high CpG region of the ERα promoter, which contains 28 CpG dinucleotides. For MDA-MB-231 and MCF-7 cell lines (10 replicates each), methylated CpGs are designated by closed circles; unmethylated CpGs are designated by open circles. (B)Statistical chart of methylation analysis; the results shown represent the means ± S.E. of three independent experiments. Significant differences from the controls as determined by Student's t test are indicated by asterisks (P <0.05).
Figure 5 Methylation analysis of the ERα promoter by BSP in breast cancer cells. (A)Shown is a representative bisulfite sequence analysis for the high CpG region of the ERα promoter, which contains 28 CpG dinucleotides. For MDA-MB-231 and MCF-7 cell lines (10 replicates each), methylated CpGs are designated by closed circles; unmethylated CpGs are designated by open circles. (B)Statistical chart of methylation analysis; the results shown represent the means ± S.E. of three independent experiments. Significant differences from the controls as determined by Student's t test are indicated by asterisks (P <0.05).CC BY · PubMed Central
Figure 6 Methylation-related proteins mediate arsenic trioxide-induced re-expression of ERα. (A) Immunoblot analysis of DNMTs and MBD2 protein. Equal amounts of protein (80 μg) from whole-cell lysates of the control MCF-7 and MDA-MB-231 cells, treated as in Fig. 1, were separated by SDS-PAGE and subjected to Western blot analysis with specific antibodies against DNMT1, DNMT3a, DNMT3b and MBD2. Equivalence of protein loading was demonstrated by immunoblotting with anti-GAPDH antibody. (B) Relative protein levels (mean± SD) of DNMTs (n = 3). (C) Relative protein levels (mean± SD) of MBD2 (n = 3). (D) ChIP analysis of association of DNMT1 and ERα promoter. Cross-linked chromatin prepared from ER-positive MCF-7 and ER-negative MDA-MB-231 human breast cancer cells was immunoprecipitated with antibodies DNMT1. MDA-MB-231 cells treated as in Fig. 1. The immunoprecipitates were subjected to PCR analysis. Aliquots of chromatin taken before immunoprecipitation were used as input controls (n = 3). # P<0.05 compared with control cells. *P<0.05 compared with cells exposed to 1μM arsenic trioxide.
Figure 6 Methylation-related proteins mediate arsenic trioxide-induced re-expression of ERα. (A) Immunoblot analysis of DNMTs and MBD2 protein. Equal amounts of protein (80 μg) from whole-cell lysates of the control MCF-7 and MDA-MB-231 cells, treated as in Fig. 1, were separated by SDS-PAGE and subjected to Western blot analysis with specific antibodies against DNMT1, DNMT3a, DNMT3b and MBD2. Equivalence of protein loading was demonstrated by immunoblotting with anti-GAPDH antibody. (B) Relative protein levels (mean± SD) of DNMTs (n = 3). (C) Relative protein levels (mean± SD) of MBD2 (n = 3). (D) ChIP analysis of association of DNMT1 and ERα promoter. Cross-linked chromatin prepared from ER-positive MCF-7 and ER-negative MDA-MB-231 human breast cancer cells was immunoprecipitated with antibodies DNMT1. MDA-MB-231 cells treated as in Fig. 1. The immunoprecipitates were subjected to PCR analysis. Aliquots of chromatin taken before immunoprecipitation were used as input controls (n = 3). # P<0.05 compared with control cells. *P<0.05 compared with cells exposed to 1μM arsenic trioxide.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 65

Metadata

Authors
Du, J., Zhou, N., Liu, H., Jiang, F., Wang, Y., Hu, C., Qi, H., Zhong, C., Wang, X., & Li, Z.
Affiliations
  • Nanjing Medical University (CN)
  • State Key Laboratory of Reproductive Medicine (CN)
Corresponding author
Li, Zhong
Venue
PLoS ONE
Published
2012-04-27
Volume
7
Issue
4
Pages
e35957
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2014235860
Cited by
65
References
43
Citations by year
2026: 1 · 2025: 4 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 5 · 2020: 6 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 10 · 2015: 2 · 2014: 10 · 2013: 6 · 2012: 1
FWCI
3.64
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (30901186, 30972507, 863 Program)
  • Priority Academic Program Development of Jiangsu Higher Education Institutions
  • Qinglan Project of Jiangsu Province of China
  • National High-tech Research and Development Program
  • National Institute on Alcohol Abuse and Alcoholism (R21AA023001)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
arsenic trioxide, estrogen receptor alpha, estrogen receptor-negative breast cancer, promoter demethylation, DNA methylation, epigenetic reprogramming, DNMT1, DNMT3A, 4-hydroxytamoxifen, fulvestrant, S-adenosylmethionine, MDA-MB-231 cells, selective estrogen receptor modulators, endocrine therapy sensitivity
MeSH terms
DNA (Cytosine-5-)-Methyltransferase 1, Arsenic Trioxide, Animals, Arsenicals, Breast Neoplasms, DNA (Cytosine-5-)-Methyltransferases, DNA-Binding Proteins, Drug Screening Assays, Antitumor, Female, Humans, Mice, Nude, Neoplasm Proteins, Oxides, Promoter Regions, Genetic, Protein Binding, RNA, Messenger, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, Sequence Analysis, DNA, CpG Islands, DNA Methylation, Cell Line, Tumor, Estrogen Receptor alpha, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.